TWI716340B - 具有ｘｔｅｎ之凝血酶可裂解連接子及其用途 - Google Patents

具有ｘｔｅｎ之凝血酶可裂解連接子及其用途 Download PDF

Info

Publication number
TWI716340B
TWI716340B TW103122511A TW103122511A TWI716340B TW I716340 B TWI716340 B TW I716340B TW 103122511 A TW103122511 A TW 103122511A TW 103122511 A TW103122511 A TW 103122511A TW I716340 B TWI716340 B TW I716340B
Authority
TW
Taiwan
Prior art keywords
vwf
fviii
domain
protein
sequence
Prior art date
Application number
TW103122511A
Other languages
English (en)
Chinese (zh)
Other versions
TW201514204A (zh
Inventor
艾可塔 喬巴拉
約翰 庫門
彤瑤 劉
Original Assignee
美商百歐維拉提夫治療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商百歐維拉提夫治療公司 filed Critical 美商百歐維拉提夫治療公司
Publication of TW201514204A publication Critical patent/TW201514204A/zh
Application granted granted Critical
Publication of TWI716340B publication Critical patent/TWI716340B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW103122511A 2013-06-28 2014-06-30 具有ｘｔｅｎ之凝血酶可裂解連接子及其用途 TWI716340B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361840872P 2013-06-28 2013-06-28
US61/840,872 2013-06-28

Publications (2)

Publication Number Publication Date
TW201514204A TW201514204A (zh) 2015-04-16
TWI716340B true TWI716340B (zh) 2021-01-21

Family

ID=52142742

Family Applications (3)

Application Number Title Priority Date Filing Date
TW103122511A TWI716340B (zh) 2013-06-28 2014-06-30 具有ｘｔｅｎ之凝血酶可裂解連接子及其用途
TW111122793A TWI844042B (zh) 2013-06-28 2014-06-30 具有xten之凝血酶可裂解連接子及其用途
TW109104938A TWI770467B (zh) 2013-06-28 2014-06-30 具有ｘｔｅｎ之凝血酶可裂解連接子及其用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW111122793A TWI844042B (zh) 2013-06-28 2014-06-30 具有xten之凝血酶可裂解連接子及其用途
TW109104938A TWI770467B (zh) 2013-06-28 2014-06-30 具有ｘｔｅｎ之凝血酶可裂解連接子及其用途

Country Status (17)

Country Link
US (3) US20160251408A1 (enExample)
EP (2) EP4368194A3 (enExample)
JP (6) JP2016523919A (enExample)
KR (4) KR102714760B1 (enExample)
CN (3) CN113817069A (enExample)
AU (3) AU2014302100B2 (enExample)
CA (1) CA2913078A1 (enExample)
CL (1) CL2015003710A1 (enExample)
EA (1) EA201592022A1 (enExample)
HK (1) HK1223302A1 (enExample)
IL (3) IL242436B (enExample)
MX (1) MX2015016567A (enExample)
NZ (1) NZ713904A (enExample)
PH (1) PH12015502614A1 (enExample)
SG (3) SG11201509313PA (enExample)
TW (3) TWI716340B (enExample)
WO (1) WO2014210558A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012004094A2 (pt) 2009-08-24 2016-03-08 Amunix Operating Inc composições de fator vii de coagulação e métodos para fazer e usar as mesmas
EA035323B1 (ru) 2012-01-12 2020-05-28 Биовератив Терапьютикс Инк. Полипептиды химерного фактора viii и их применение
HRP20221531T1 (hr) 2012-02-15 2023-02-17 Bioverativ Therapeutics Inc. Pripravci faktora viii i postupci dobivanja i korištenja istih
LT2822577T (lt) 2012-02-15 2019-03-25 Bioverativ Therapeutics Inc. Rekombinantiniai faktoriaus viii baltymai
WO2014008480A2 (en) 2012-07-06 2014-01-09 Biogen Idec Ma Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
US10138291B2 (en) 2012-07-11 2018-11-27 Bioverativ Therapeutics Inc. Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
DK3091997T5 (da) * 2014-01-10 2024-10-14 Bioverativ Therapeutics Inc Kimære faktor viii-proteiner og anvendelser deraf
AU2016231328B2 (en) * 2015-03-06 2018-07-05 CSL Behring Lengnau AG Compounds for improving the half-life of von Willebrand factor
MX2018001497A (es) 2015-08-03 2018-05-15 Bioverativ Therapeutics Inc Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
JP6877469B2 (ja) 2016-06-24 2021-05-26 モガム・インスティテュート・フォー・バイオメディカル・リサーチＭｏｇａｍ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ Ｆｖｉｉｉおよびｖｗｆ因子を含むキメラタンパク質、ならびにそれらの使用
TW201828975A (zh) * 2016-11-11 2018-08-16 瑞士商Ｃｓｌ貝林重組技能公司 用於治療血友病之截短型類血友病因子（ｖｏｎ Ｗｉｌｌｅｂｒａｎｄ ｆａｃｔｏｒ）多肽類
WO2018102743A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
RS66972B1 (sr) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc Metode lečenja hemofilije a
IL280880B2 (en) 2018-08-27 2025-04-01 Regeneron Pharma Using Raman Spectroscopy in Downstream Purification

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110069164A1 (en) * 2009-09-24 2011-03-24 Fujifilm Corporation Endoscope system
CN102076855A (zh) * 2008-06-24 2011-05-25 Csl百灵有限公司 具有延长的体内半衰期的因子viii，冯·维勒布兰德因子或它们的复合物
CN102348715A (zh) * 2009-02-03 2012-02-08 阿穆尼克斯运营公司 延伸重组多肽和包含该延伸重组多肽的组合物
US20130017997A1 (en) * 2010-08-19 2013-01-17 Amunix Operating Inc. Factor VIII Compositions and Methods of Making and Using Same

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5981216A (en) 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
JPH0788399B2 (ja) 1985-04-12 1995-09-27 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド 新規プロコアギュラント蛋白質
KR910006424B1 (ko) 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
EP0253870B1 (en) 1986-01-03 1993-03-31 Genetics Institute, Inc. Method for producing factor viii:c-type proteins
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5610278A (en) 1986-06-24 1997-03-11 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
US6060447A (en) 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
IL86693A (en) 1987-06-12 1994-06-24 Stichting Centraal Lab Proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5846951A (en) 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US6037452A (en) * 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
JP2003526625A (ja) * 1999-07-23 2003-09-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 血小板の活性化の調節
CA2405550A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
WO2001087922A2 (en) 2000-05-16 2001-11-22 Lipoxen Technologies Limited Derivatisation of proteins in aqueous solution
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
CA2440582A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
KR101271635B1 (ko) 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
CN100343393C (zh) 2002-03-15 2007-10-17 布赖汉姆妇女医院 适合治疗剂全身性递送的中央气道给药
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
AU2004215912B2 (en) 2003-02-26 2009-03-26 Nektar Therapeutics Polymer-factor VIII moiety conjugates
WO2004076484A1 (en) * 2003-02-27 2004-09-10 National Research Council Of Canada Peptide inhibitors of thrombin as potent anticoagulants
KR101113726B1 (ko) 2003-08-12 2012-02-27 리폭센 테크놀로지즈 리미티드 단백질 유도 및 컨쥬게이션용 시알산 유도체
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
GB0516091D0 (en) * 2005-08-04 2005-09-14 Haemostatix Ltd Therapeutic agent
KR20080071119A (ko) 2005-08-12 2008-08-01 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
AU2007294805A1 (en) 2006-09-14 2008-03-20 Human Genome Sciences, Inc. Albumin fusion proteins
US20100041872A1 (en) * 2006-10-04 2010-02-18 Defrees Shawn Glycerol linked pegylated sugars and glycopeptides
EP3231440A1 (en) * 2006-12-22 2017-10-18 CSL Behring GmbH Modified coagulation factors with prolonged in vivo half-life
DE602008005596D1 (de) 2007-06-21 2011-04-28 Univ Muenchen Tech Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
BRPI0820271A2 (pt) * 2007-11-09 2015-05-26 Baxter Int Métodos de aumentar a sobrevivência de uma proteína de coagulação pela inibição da interação com um receptor de depuração, de aumentar a sobrevivência de fator viii que inibe receptores de depruração de proteína de coagulação, de tratar um indivíduo com uma doença de coagulação sanguínea, e de tratar uma doença que tem por característica uma deficiência de fator viii em um indivíduo, e, proteína de ...métodos de aumentar a sobrevivência de uma proteína de coagulação pela inibição da interação com um receptor de depuração, de aumentar a sobrevivência de fator viii pela inibição da interação com um receptor de depuração, de preparar uma composição que inibe receptores de depuração de proteína de coagulação, de tratar um indivíduo com uma doença de coagulação sanguínea, e de tratar uma doença que tem por característica uma deficiência de fator viii em um indivíduo, e, proteína de coagulação modificada.
WO2010060081A1 (en) * 2008-11-24 2010-05-27 Bayer Healthcare Llc Method of determining pegylated blood coagulation factor activity in a silica-based activated partial thromboplastin time assay
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
CN102427823A (zh) * 2009-03-24 2012-04-25 拜耳医药保健有限公司 因子viii变体及使用方法
AU2010258892B2 (en) 2009-06-08 2015-08-13 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
AU2010258898B8 (en) 2009-06-08 2015-02-05 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
BR112012004094A2 (pt) 2009-08-24 2016-03-08 Amunix Operating Inc composições de fator vii de coagulação e métodos para fazer e usar as mesmas
WO2011028344A2 (en) 2009-08-25 2011-03-10 Amunix Operating Inc. Interleukin-1 receptor antagonist compositions and methods of making and using same
MX2012005527A (es) * 2009-11-13 2012-08-08 Grifols Therapeutics Inc Preparaciones que contienen el factor de von willebrand (fvw) procedimientos, kits y aplicaciones relacionados con las mismas.
MX353233B (es) * 2009-12-06 2018-01-08 Bioverativ Therapeutics Inc Polipéptidos híbridos y quiméricos del factor viii-fc, y métodos de uso de los mismos.
WO2011084808A2 (en) * 2009-12-21 2011-07-14 Amunix Operating Inc. Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
US9611310B2 (en) 2010-07-09 2017-04-04 Bioverativ Therapeutics Inc. Systems for factor VIII processing and methods thereof
WO2012006635A1 (en) 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Processable single chain molecules and polypeptides made using same
EA035323B1 (ru) * 2012-01-12 2020-05-28 Биовератив Терапьютикс Инк. Полипептиды химерного фактора viii и их применение
LT2822577T (lt) 2012-02-15 2019-03-25 Bioverativ Therapeutics Inc. Rekombinantiniai faktoriaus viii baltymai
HRP20221531T1 (hr) * 2012-02-15 2023-02-17 Bioverativ Therapeutics Inc. Pripravci faktora viii i postupci dobivanja i korištenja istih
US20150080309A1 (en) * 2012-04-24 2015-03-19 Nova Nordisk A/S Compounds Suitable for Treatment of Haemophilia
US10138291B2 (en) * 2012-07-11 2018-11-27 Bioverativ Therapeutics Inc. Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof
DK2796145T3 (da) * 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
TW201536811A (zh) * 2013-05-31 2015-10-01 Biogen Idec Inc 嵌合ｆｖｉｉ－ｘｔｅｎ分子及其用途
WO2014210547A1 (en) * 2013-06-28 2014-12-31 Biogen Idec Ma Inc. Thrombin cleavable linker
DK3091997T5 (da) * 2014-01-10 2024-10-14 Bioverativ Therapeutics Inc Kimære faktor viii-proteiner og anvendelser deraf
RS66972B1 (sr) * 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc Metode lečenja hemofilije a

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102076855A (zh) * 2008-06-24 2011-05-25 Csl百灵有限公司 具有延长的体内半衰期的因子viii，冯·维勒布兰德因子或它们的复合物
CN102348715A (zh) * 2009-02-03 2012-02-08 阿穆尼克斯运营公司 延伸重组多肽和包含该延伸重组多肽的组合物
US20110069164A1 (en) * 2009-09-24 2011-03-24 Fujifilm Corporation Endoscope system
US20130017997A1 (en) * 2010-08-19 2013-01-17 Amunix Operating Inc. Factor VIII Compositions and Methods of Making and Using Same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Marvin T. Nieman, and Alvin H. Schmaier "Interaction of thrombin with PAR1 and PAR4 at the thrombin cleavage site" Biochemistry, 46(29): 8603–8610, 2007/07/24 *

Also Published As

Publication number Publication date
IL266462B (en) 2022-12-01
KR102666819B1 (ko) 2024-05-23
CN113817069A (zh) 2021-12-21
TW202313672A (zh) 2023-04-01
CN105392495A (zh) 2016-03-09
AU2014302100B2 (en) 2020-02-13
US20240083975A1 (en) 2024-03-14
IL297611A (en) 2022-12-01
IL297611B1 (en) 2025-07-01
EP4368194A3 (en) 2024-07-31
JP2016523919A (ja) 2016-08-12
IL242436B (en) 2019-05-30
JP2022000053A (ja) 2022-01-04
KR20230007555A (ko) 2023-01-12
IL266462B2 (en) 2023-04-01
MX2015016567A (es) 2016-03-31
IL266462A (en) 2019-06-30
KR20160023654A (ko) 2016-03-03
EP4368194A2 (en) 2024-05-15
CL2015003710A1 (es) 2016-08-26
AU2014302100A1 (en) 2015-11-26
CA2913078A1 (en) 2014-12-31
AU2020203063B2 (en) 2023-05-25
CN113831415A (zh) 2021-12-24
EP3013358A1 (en) 2016-05-04
TWI770467B (zh) 2022-07-11
EA201592022A1 (ru) 2016-05-31
KR102865153B1 (ko) 2025-09-29
NZ713904A (en) 2022-02-25
AU2023219840A1 (en) 2023-09-14
KR102714760B1 (ko) 2024-10-11
JP2019010124A (ja) 2019-01-24
JP7005800B2 (ja) 2022-02-10
EP3013358A4 (en) 2017-03-22
BR112015031194A2 (pt) 2017-09-19
AU2020203063A1 (en) 2020-05-28
TW201514204A (zh) 2015-04-16
SG10201913738YA (en) 2020-03-30
JP2025061316A (ja) 2025-04-10
WO2014210558A1 (en) 2014-12-31
HK1223302A1 (zh) 2017-07-28
KR20240148954A (ko) 2024-10-11
US20160251408A1 (en) 2016-09-01
SG11201509313PA (en) 2016-01-28
JP7297837B2 (ja) 2023-06-26
PH12015502614A1 (en) 2016-02-29
US20220106383A1 (en) 2022-04-07
JP7623426B2 (ja) 2025-01-28
JP2023107932A (ja) 2023-08-03
IL297611B2 (en) 2025-11-01
KR102714760B9 (ko) 2025-09-15
TW202045535A (zh) 2020-12-16
KR20240023705A (ko) 2024-02-22
TWI844042B (zh) 2024-06-01
JP2021072853A (ja) 2021-05-13
SG10201710616XA (en) 2018-02-27

Similar Documents

Publication Publication Date Title
TWI716340B (zh) 具有ｘｔｅｎ之凝血酶可裂解連接子及其用途
TWI727187B (zh) 嵌合因子viii多肽及其用途
TWI667258B (zh) 因子ｖｉｉｉ與ｘｔｅｎ及范威爾邦德（ｖｏｎ ｗｉｌｌｅｂｒａｎｄ）因子蛋白質之複合物及其用途
TWI667255B (zh) 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
JP7217630B2 (ja) 最適化第ｖｉｉｉ因子遺伝子
TW201542596A (zh) 凝血酶可裂解連接子
BR112016015512B1 (pt) Proteína quimérica, composição farmacêutica e seus usos
CN106659771B (zh) 修饰的von Willebrand因子
JP2022514465A (ja) 第ｉｘ因子を発現するレンチウイルスベクターの使用
HK40111404A (en) Thrombin cleavable linker with xten and its uses thereof
BR112015031194B1 (pt) Molécula quimérica, composição farmacêutica, e uso dos anteriores
HK40099494A (en) Factor viii complex with xten and von willebrand factor protein, and uses thereof
HK1211228B (en) Factor viii complex with xten and von willebrand factor protein, and uses thereof